Grail vs Pacific Biosciences Of California
Grail and Pacific Biosciences Of California are similar in size: $147m and $160m of revenue in their latest fiscal years. Grail grew faster (17.2% against 3.9%). Grail kept more of each dollar of sales as profit: a net margin of -277.5% against -341.5%. Grail carries less debt relative to equity (0.0% against 12065.5%).
| Latest fiscal year | GrailGRAL, 2025 | Pacific Biosciences Of CaliforniaPACB, 2025 |
|---|---|---|
| Revenue | $147m | $160m |
| Revenue growth | 17.2% | 3.9% |
| Net income | −$408m | −$546m |
| Operating margin | -382.0% | -346.2% |
| Net margin | -277.5% | -341.5% |
| Return on equity | -16.1% | — |
| Free cash flow | −$300m | −$114m |
| Cash | $250m | $63.7m |
| Total debt | $0 | $645m |
| Debt to equity | 0.0% | 12065.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 910 | 485 |
| Market value | $6.25bn | $763m |
| Price vs our value range | — | — |
| Moat score | — | 13 (Weak) |
| Insider trades, 12 months | 0 buys, 47 sales | 0 buys, 12 sales |